BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 4048971)

  • 21. [Intraperitoneal cisplatin chemotherapy for ovarian cancer].
    Hayashi H; Nishii H; Ueda K; Kunitou S; Wada S; Takanashi H; Kobayashi S; Yasuda M
    Gan To Kagaku Ryoho; 2001 Dec; 28(13):2043-8. PubMed ID: 11791382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraperitoneal chemotherapy: a reemerging approach in the treatment of ovarian cancer.
    Drake B
    J Infus Nurs; 2009; 32(6):314-22. PubMed ID: 19918140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal chemotherapy in ovarian cancer.
    Hofstra LS; de Vries EG; Mulder NH; Willemse PH
    Cancer Treat Rev; 2000 Apr; 26(2):133-43. PubMed ID: 10772970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal chemotherapy in the management of malignant disease.
    Markman M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):142-8. PubMed ID: 12113122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
    Malmström H; Carstensen J; Simonsen E
    Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal chemotherapy in the management of ovarian cancer.
    Ozols R
    Semin Oncol; 1985 Sep; 12(3 Suppl 4):75-80. PubMed ID: 4048980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of complications associated with catheter intraperitoneal chemotherapy of ovarian carcinoma].
    Wei LH; Qian HN; Li WF
    Zhonghua Fu Chan Ke Za Zhi; 1994 Dec; 29(12):732-4, 762-3. PubMed ID: 7712902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
    Bamba T; Kanda T; Ohashi M; Hanyu T; Sakamoto K; Ishikawa T; Yajima K; Makino S; Tanabe T; Kosugi S; Hatakeyama K
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1695-7. PubMed ID: 16315912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peritoneal cytology of ovarian cancer patients receiving intraperitoneal therapy: quantitation of malignant cells and response.
    Sagae S; Berek JS; Fu YS; Chang N; Dauplat J; Hacker NF
    Obstet Gynecol; 1988 Nov; 72(5):782-8. PubMed ID: 3173930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.
    Myers C
    Semin Oncol; 1984 Sep; 11(3):275-84. PubMed ID: 6385257
    [No Abstract]   [Full Text] [Related]  

  • 32. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer.
    Meunier F; van der Auwera P; Aoun M; Piccart M; Sculier JP
    Scand J Infect Dis Suppl; 1990; 72():26-8. PubMed ID: 2151063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C; Huang R; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
    Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution of intraperitoneal chemotherapy into the pleural cavity.
    Vaccarello L; Berghella V; Rubin SC; Hoskins WJ
    Obstet Gynecol; 1994 Oct; 84(4 Pt 2):714-7. PubMed ID: 9205461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
    Black D; Levine DA; Nicoll L; Chou JF; Iasonos A; Brown CL; Sonoda Y; Chi DS; Leitao MM; Abu-Rustum NR; Ferguson SE; Barakat RR
    Gynecol Oncol; 2008 Apr; 109(1):39-42. PubMed ID: 18234300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
    Almadrones L
    Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].
    Vaira M; Scuderi S; Costamagna D; Barone R; Aghemo B; Mioli PR; De Simone M
    Minerva Chir; 2002 Oct; 57(5):597-605. PubMed ID: 12370661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.